Kimberly Hummer, MD
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1881829455
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in OK, where the typical reported total is $2,620.
Across 95 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$387
- Medtronic$181
- Sanofi-aventis U.S. LLC$167
- Amgen$155
- Dexcom, Inc.$146
- Lilly USA, LLC$146
- plus $510 from 15 others
What the payments were for
- Food & beverage$1,694100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 19 | $387 |
| Medtronic | 11 | $181 |
| Sanofi-aventis U.S. LLC | 9 | $167 |
| Amgen(2 entities) | 9 | $155 |
| Dexcom, Inc. | 7 | $146 |
| Lilly USA, LLC | 9 | $146 |
| Recordati_rare_diseases_inc. | 4 | $96 |
| Abbott | 3 | $54 |
| Boehringer Ingelheim | 3 | $48 |
| Ultragenyx Pharmaceutical Inc. | 3 | $42 |
| Merck | 3 | $41 |
| Amryt Pharma Holdings Ltd | 2 | $41 |
| IBSA Pharma Inc. | 2 | $31 |
| RGH Enterprises LLC | 1 | $30 |
| BETA Bionics, Inc. | 2 | $29 |
| Johnson & Johnson | 2 | $24 |
| Novo Nordisk | 2 | $23 |
| Mannkind Corporation | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| Cequr Corporation | 1 | $5 |
How this compares
$1,694 in reported general payments places this provider in the 40th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 473 | $725,435 |
| JardianceEmpagliflozin | 291 | $345,860 |
| TrulicityDulaglutide | 165 | $236,994 |
| MounjaroTirzepatide | 131 | $171,407 |
| Tresiba Flextouch U-200Insulin Degludec | 63 | $108,732 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $106,963 |
| FarxigaDapagliflozin Propanediol | 76 | $93,530 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 91 | $77,073 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 105 | $70,512 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $58,689 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $58,015 |
| JanuviaSitagliptin Phosphate | 51 | $53,102 |
| Humalog Kwikpen U-100Insulin Lispro | 92 | $46,028 |
| RybelsusSemaglutide | 24 | $42,715 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 214 | $40,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $23 | $782,584520 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $146 | $429,723346 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $48 | $394,563341 claims |
| MerckJanuvia, Janumet | $41 | $72,63567 claims |
| Sanofi-aventis U.S. LLCLantus | $167 | $3,97118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Oklahoma City
- Christian MangrumOklahoma City$54K
- Robert ScofieldOklahoma City$15K
- Donny WynnOklahoma City$11K
- Cheryl BlackOklahoma City$8K
- Diana KennedyOklahoma City$8K
- Ali TipuOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.